Thrilled to share our ARCHES external validation of NADIR, now in Cancer! In 558 men with mAPMS on enzalutamide, NADIR showed AUC 0.80 w/ strong calibration for predicting PSA ≤0.2 by 6 months. acsjournals.onlinelibrary.wi… @neerajaiims @DrRanaMcKay @AarmstrongDuke @DrSpratticus

Thrilled to share I've received the NIH/NCI K99/R00 Award! Deeply grateful to my mentor @mishabeltran for her immense support, my advisory committee and referees, and to @PCF_Science and DoD for early funding that made this possible.

🚨Outstanding @PCFnews @PCF_Science Opportunity! PCF Leadership Academy: Dec 3-5, 2026, Santa Monica, CA Equipping the next gen to take care of advanced PCa Eligibility: 🇺🇸-based, entering/recently started in Onc or Uro community practice Apply: pcf.org/our-impact/medical-r…

Just in👉today @US_FDA approved Pluvicto (Lutetium-177)for PSMA+ metastatic androgen pathway modulation-sensitive #prostatecancer (mAPMS/mHSPC), based on the results of ph3 PSMAddition trial👇 @PCF_Science @urotoday @OncoAlert Congrats @DrScottTagawa & team

Proud to be part of the #PSMAAddition team and our site @CleClinicMD to be the highest-enrolling U.S. site! Great to have this as an option for patients and deepest thanks to our patients, families, co-investigators and reserach teams who made this possible. @ChrisWeeMD @AmandaNizamMD @MosheOrnsteinMD @jamecancerdoc @caseccc @PBarataMD @OncBrothers @OncoAlert @PCF_Science

Congratulations to our 2026 Young Investigator Award winners Kondapa Naidu Bobba, PhD, and George Diehl, PhD. Together PCF and @SNM_MI is committed to investing in the next generation of prostate cancer researchers. Learn more: snmmi.org/Web/News/Articles/…

In the MRI era, not all lesions carry the same risk, how do we risk-stratify them more precisely? In our paper in @EurUrolFocus, we propose PSA density cutoffs tailored to lesion suspicion: 0.15 for PI-RADS 1–2 and 0.10 for PI-RADS ≥3. @PeterPintoMD @MillanBraden @PCF_Science

Evaluating the impact of #RLT on clonal hematopoiesis #CHIP: our experience with #LuPSMA published in @JournalofNucMed @SNM_MI jnm.snmjournals.org/content/… @DanaFarber_GU @adamssperling @Lachelle_Dawn @HJacene @PCF_Science @urotoday 1/3

Thanks so much @urotoday @PCF_Science and of course @neerajaiims. Dr. Agarwal, I am deeply grateful for your kind support 🙏. And as always no work is done without @DrSpratticus being there for me.

🚨 PSA can be flat while #prostatecancer grows 🚨 @JCO_ASCO 👥 >2,500 pts, advanced PCa 📊 pooled ARCHES + PROSPER, enzalutamide 📊 radiographic progression vs PSA change ✅ ~1 in 4 had progression on imaging w/ stable or undetectable PSA ✅ those pts had worse survival ⚠️ post-hoc, ARSI-treated pts only 🎯 on potent AR inhibitors, PSA is necessary but not sufficient. scan f/u matters, esp the first 2 yrs. @PCFnews @PCF_Science @AarmstrongDuke

🚨active surveillance, for #prostatecancer, now with a 25-year horizon🚨 @EUplatinum 📊 GÖTEBORG-1, screen-detected low- and intermediate-risk PCa, f/u up to 25 yrs ✅ extended data continue to support AS as safe for well-selected pts over the very long term ⚠️ intermediate-risk selection and adherence to follow-up still matter, this is screen-detected disease ⭐️PCa-specific survival at 25 yrs was 94% -99% for VLR -92% for LR -85% for Int Risk 🎯 bottom line: when we tell a pt w/with low-risk PCa that surveillance is safe, we can now point to a quarter century of trial follow-up. 🔗 shorturl.at/H2a6x #pcsm @AmerUrological @UroOnc @GGiannarini @PCFnews @PCF_Science @GabeCanales @ASPI_INTL

1/3 We know 3βHSD1 catalyzes an essential step to make androgens from extra-gonadal precursors including DHEA & cholesterol. That means its most important in men treated w/gonadal T depletion. But it also does something else that could be important in eugonadal men! @PCF_Science

The FDA approved LuPSMA (Pluvicto) + androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer. Approval is based on the PSMAddition trial. Congrats to everyone whose hard work led to this new option for patients!👏

So proud to celebrate Melanie on receiving the NOA for her NIH F31 Fellowship! 🎉 She is now the third graduate student in the Mu Lab to earn an NIH F31 or NSF Graduate Fellowship. A well-deserved achievement, and I’m excited to see all that lies ahead! @Yale_Urology @YaleMed

Just witnessed an incredible conversation between two powerhouse women leaders in prostate cancer research. Dr. Karen Knudsen’s innovation and breaking barriers are absolute must-watch. @AndreaMiyahira @DrKarenKnudsen @PCF_Science

Comparing cognitive change on enzalutamide and darolutamide in the #ARACOG trial. @CaPsurvivorship @DanaFarber sits down with @zklaassen_md @GACancerCenter to discuss the ARACOG randomized trial comparing cognitive outcomes between darolutamide and enzalutamide in advanced prostate cancer, which enrolled patients from 2021 to 2024 with 48 weeks of follow-up, using the maximally changed cognitive domain at 24 weeks as the primary endpoint, assessed by computer-based testing and patient-reported outcomes. #WatchNow > bit.ly/3SrdNDI

Building a transformative career across academia, advocacy, and biotech. @DrKarenKnudsen @parkerici joins @AndreaMiyahira @PCFnews to discuss her career trajectory and leadership philosophy, tracing her path from PCF-funded #ProstateCancer researcher to CEO of the Parker Institute for Cancer Immunotherapy. #WatchNow on UroToday > bit.ly/3RtM6tR

Genomic risk stratification in metastatic hormone-sensitive #ProstateCancer with STRATOS-P. @mwschoen @SLU_Official joins @TDorffOnc @cityofhope to discuss STRATOS-P, a genomic risk classification derived from next-generation sequencing data on over 2,000 veterans with metastatic hormone-sensitive prostate cancer. Analysis of more than 300 genes identified 16 prognostic for overall survival, with alterations in tumor suppressor genes including TP53, PTEN, and RB1 defining the unfavorable risk group. #WatchNow > bit.ly/4b22WGW

Beyond PSMA with STEAP1, DLL3, and H7B3 as emerging radioligand targets. @RenuEapen @PeterMacCC joins @zklaassen_md @GACancerCenter to discuss the current state and future directions of radioligand therapy in prostate cancer, using lutetium PSMA trial data across disease states to distinguish where standard-of-care use is established from settings still under active investigation. #WatchNow > bit.ly/4yACe1V

BRCAAway trial investigates combination vs sequencing of ARPI and PARP inhibitor in #mCRPC. Maha Hussain, MD, FACP, FASCO @LurieCancer joins @neerajaiims @huntsmancancer to discuss overall survival data from BRCAAway, a phase 2 trial comparing upfront combination abiraterone plus olaparib against monotherapy with sequencing in HRR-mutated metastatic castration-resistant prostate cancer. #WatchNow > bit.ly/4c1uRqG